NMDAR AUTOIMMUNE ENCEPHALITIS
Clinical trials for NMDAR AUTOIMMUNE ENCEPHALITIS explained in plain language.
Never miss a new study
Get alerted when new NMDAR AUTOIMMUNE ENCEPHALITIS trials appear
Sign up with your email to follow new studies for NMDAR AUTOIMMUNE ENCEPHALITIS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug trial aims to tame rare brain inflammation
Disease control Recruiting nowThis Phase 3 trial tests satralizumab, an injected drug, in 120 people with NMDAR or LGI1 encephalitis—rare conditions where the immune system attacks the brain. The goal is to see if the drug improves disability and reduces the need for rescue treatments. Participants receive ei…
Matched conditions: NMDAR AUTOIMMUNE ENCEPHALITIS
Phase: PHASE3 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
Life after brain inflammation: new study probes hidden scars of rare disease
Knowledge-focused Recruiting nowThis study looks at the long-term social and emotional challenges faced by people who have had NMDA receptor encephalitis, a rare brain inflammation. Researchers will ask 30 adults to complete questionnaires about fatigue, anxiety, depression, sleep, and quality of life. The goal…
Matched conditions: NMDAR AUTOIMMUNE ENCEPHALITIS
Sponsor: Hospices Civils de Lyon • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:06 UTC